Marta Casini

Marta Casini

Auto-generated profile, based on publicly available information

Marta Casini

Dept of Biomedical Sciences, Humanitas University, Milan, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
Giovanni PaolettiGiovanni Paoletti
Giovanni Paoletti
JPJack Pepys
Jack Pepys
MCMarta Casini
Marta Casini
Danilo Di BonaDanilo Di Bona
Danilo Di Bona
Enrico HefflerEnrico Heffler
Enrico Heffler
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the management of severe asthma has been a significant challenge historically. The introduction of novel biologic drugs in the past few decades has revolutionised the field, presenting physicians with a variety of biologic drugs with different mechanisms for the treatment of severe asthma.It is of crucial importance to evaluate the effectiveness of these drugs by following their “real-life” effectiveness rather than relying solely on their efficacy, established in carefully designed clinical trials, which therefore do not necessarily match the profile of the real-life patient. Understanding the actual effectiveness of the specific drugs in real-life patients is a crucial part of tailoring the right drugs to the right patients. Registries serve as an important tool in obtaining real-life evidence, since they are in effect observational studies, following the entire patient population.